Related references
Note: Only part of the references are listed.Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs
R. K. Jackso et al.
CLINICAL ONCOLOGY (2019)
Oxygen-sensitive MRI assessment of tumor response to hypoxic gas breathing challenge
Donghan M. Yang et al.
NMR IN BIOMEDICINE (2019)
Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI
James P. B. O'Connor et al.
BRITISH JOURNAL OF RADIOLOGY (2019)
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Jacob P. Laubach et al.
CLINICAL CANCER RESEARCH (2019)
Rationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies
Mark W. Dewhirst et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials
Linda Spiegelberg et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2019)
Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies
Yoichi Takakusagi et al.
ANTIOXIDANTS & REDOX SIGNALING (2018)
Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice
Shingo Matsumoto et al.
CANCER RESEARCH (2018)
Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism
Martin Benej et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
Priyamvada Jayaprakash et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
A potential solution for eliminating hypoxia as a cause for radioresistance
Mark W. Dewhirst
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Limitations of oxygen delivery to cells in culture: An underappreciated problem in basic and translational research
Trenton L. Place et al.
FREE RADICAL BIOLOGY AND MEDICINE (2017)
The Solid Mechanics of Cancer and Strategies for Improved Therapy
Triantafyllos Stylianopoulos
JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME (2017)
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
William D. Tap et al.
LANCET ONCOLOGY (2017)
A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model
Carla Hajj et al.
TRANSLATIONAL ONCOLOGY (2017)
Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts
Catherine S. Wegner et al.
ACTA ONCOLOGICA (2017)
Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy
Natalia Baran et al.
CLINICAL CANCER RESEARCH (2017)
Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models
James P. B. O'Connor et al.
CANCER RESEARCH (2016)
Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
Francis W. Hunter et al.
BRITISH JOURNAL OF CANCER (2016)
MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts
Xiaomeng Zhang et al.
PLOS ONE (2016)
Fundamentals of cancer metabolism
Ralph J. DeBerardinis et al.
SCIENCE ADVANCES (2016)
MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging
Sarah G. J. A. Peeters et al.
CLINICAL CANCER RESEARCH (2015)
Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302
Jonathan W. Wojtkowiak et al.
CANCER & METABOLISM (2015)
The Role of Mechanical Forces in Tumor Growth and Therapy
Rakesh K. Jain et al.
ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 16 (2014)
Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5
Jingli Wang et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Pyruvate Induces Transient Tumor Hypoxia by Enhancing Mitochondrial Oxygen Consumption and Potentiates the Anti-Tumor Effect of a Hypoxia-Activated Prodrug TH-302
Yoichi Takakusagi et al.
PLOS ONE (2014)
Altering the Response to Radiation: Sensitizers and Protectors
Deborah E. Citrin et al.
SEMINARS IN ONCOLOGY (2014)
Coevolution of Solid Stress and Interstitial Fluid Pressure in Tumors During Progression: Implications for Vascular Collapse
Triantafyllos Stylianopoulos et al.
CANCER RESEARCH (2013)
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
Qian Liu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
Jessica D. Sun et al.
CLINICAL CANCER RESEARCH (2012)
Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
Fanying Meng et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model
Julio Cardenas-Rodriguez et al.
MAGNETIC RESONANCE IMAGING (2012)
Dynamic contrast-enhanced imaging techniques: CT and MRI
J. P. B. O'Connor et al.
BRITISH JOURNAL OF RADIOLOGY (2011)
Antiangiogenic Agent Sunitinib Transiently Increases Tumor Oxygenation and Suppresses Cycling Hypoxia
Shingo Matsumoto et al.
CANCER RESEARCH (2011)
Low-Field Magnetic Resonance Imaging to Visualize Chronic and Cycling Hypoxia in Tumor-Bearing Mice
Hironobu Yasui et al.
CANCER RESEARCH (2010)
Oxygen Consumption Can Regulate the Growth of Tumors, a New Perspective on the Warburg Effect
Yijun Chen et al.
PLOS ONE (2009)
FDG uptake, a surrogate of tumour hypoxia?
Rudi Andre Dierckx et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Strategies for improved temporal and spectral resolution in in vivo oximetric imaging using time-domain EPR
Nallathamby Devasahayam et al.
MAGNETIC RESONANCE IN MEDICINE (2007)
MR assessment of changes of tumor in response to hyperbaric oxygen treatment
Ken-ichiro Matsumoto et al.
MAGNETIC RESONANCE IN MEDICINE (2006)
Electron paramagnetic resonance imaging of tumor hypoxia:: Enhanced spatial and temporal resolution for in vivo pO2 determination
K Matsumoto et al.
MAGNETIC RESONANCE IN MEDICINE (2006)
Exploiting tumour hypoxia in cancer treatment
JM Brown et al.
NATURE REVIEWS CANCER (2004)
Inhibition of mitochondrial respiration - A novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism
H Pelicano et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Single-point (constant-time) imaging in radiofrequency Fourier transform electron paramagnetic resonance
S Subramanian et al.
MAGNETIC RESONANCE IN MEDICINE (2002)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Parallel coil resonators for time-domain radiofrequency electron paramagnetic resonance imaging of biological objects
N Devasahayam et al.
JOURNAL OF MAGNETIC RESONANCE (2000)
Share Paper
